People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in  brain atrophy seen with ibudilast treatment in the SPRINT‐MS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident among PPMS patients than those with secondary progressive MS (SPMS), its researchers reported, possibly due to the new finding that untreated PPMS patients had a “significantly higher rate of atrophy” than…

You must be logged in to read/download the full post.